Company profile: hVIVO
1.1 - Company Overview
Company description
- Provider of human challenge trials to accelerate early clinical development in respiratory and infectious diseases; volunteer recruitment via FluCamp; virology and immunology lab services (hLAB) for preclinical and clinical respiratory drug and vaccine R&D; drug development consultancy and clinical trial design/execution through Venn Life Sciences; and vaccine development via Imutex.
Products and services
- HLAB: Laboratory-grade virology and immunology services supporting pre-clinical and clinical respiratory drug and vaccine discovery and development, underpinning infectious disease research needs for hVIVO programs
- Human Challenge Trials: Human-based trials that test vaccines and therapeutics for respiratory and infectious diseases, delivering early clinical development services to biopharma and accelerating drug discovery and development
- Venn Life Sciences: Clinical-grade hVIVO division that offers drug development consultancy, clinical trial design, and execution services for biopharma programs
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to hVIVO
CU Chemie Uetikon
HQ: Germany
Website
- Description: Provider of chemical and pharmaceutical production services via a state-of-the-art multi purpose plant in Europe, featuring a high standard cGMP API-production facility (MPA P3) on its manufacturing site in Lahr, Germany. Core competence includes the custom synthesis of Fine Chemical Intermediates.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CU Chemie Uetikon company profile →
Surface Ophthalmics
HQ: United States
Website
- Description: Provider of ophthalmic therapeutics leveraging the Klarity delivery vehicle, including SURF-100 topical eyedrops for chronic dry eye (Phase II), SURF-200 for acute dry eye (Phase II), SURF-201 Betamethasone 0.2% solution for post-cataract pain and inflammation (positive Phase II), and an MPA 0.1% chronic dry eye therapy ready for Phase III.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Surface Ophthalmics company profile →
US Pharma Lab
HQ: United States
Website
- Description: Provider of custom development, manufacturing, and supply services for premium dietary supplement ingredients, premixes, and products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full US Pharma Lab company profile →
Medpace
HQ: United States
Website
- Description: Provider of clinical development services as a global clinical research organization for pharmaceutical and biotechnology industries, offering integrated clinical trial support including central and bioanalytical laboratories, imaging and ECG core labs, a Phase I unit, CTMS, therapeutic expertise, decentralized trial capabilities, and remote biosensing technologies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Medpace company profile →
Therapak
HQ: United States
Website
- Description: Provider of diagnostic and medical device kitting services for clinical trials and healthcare, including protocol management, kit development, global distribution, and configurable collection kits, supported by PASSPORT online systems. Offers clinical supply packaging for temperature-sensitive shipments, specialized specimen collection and transport products, including customizable test-specific kits and temperature-controlled shipping systems, and an online hazardous materials training course.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Therapak company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for hVIVO
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to hVIVO
2.2 - Growth funds investing in similar companies to hVIVO
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for hVIVO
4.2 - Public trading comparable groups for hVIVO
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →